You are here
SYNERGENE THERAPEUTICS, INC.
UEI: W8E3G5851JK4
# of Employees: 3
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
A Dual Molecular/Targeting Therapy for PanCa
Amount: $158,980.00DESCRIPTION (provided by applicant): Approximately 30,000 people in the United States are diagnosed each year with pancreatic Cancer (PanCa). Over 90% of these will die of the disease making PanCa one ...
STTRPhase I2003Department of Health and Human Services National Institutes of Health -
TARGETING STEALTH LIPOSOME FOR CANCER GENE THERAPY
Amount: $138,762.00Advanced prostate cancer tends to be relatively refractory to standard chemotherapeutic agents, and this chemoresistance correlates with a lack of functional p53. Our preliminary data indicate that ca ...
STTRPhase I2002Department of Health and Human Services National Institutes of Health -
IMMUNOLIPOSOME-MEDIATED GENE THERAPY FOR PROSTATE CANCER
Amount: $634,660.00DESCRIPTION (provided by applicant): Advanced prostate cancer tends to be relatively refractory to standard chemotherapeutic agents and radiation treatment, and this resistance correlates with a lack ...
STTRPhase II2002Department of Health and Human Services National Institutes of Health -
IMMUNOLIPOSOME-MEDIATED GENE THERAPY FOR PROSTATE CANCER
Amount: $0.00DESCRIPTION (provided by applicant): Advanced prostate cancer tends to be relatively refractory to standard chemotherapeutic agents and radiation treatment, and this resistance correlates with a lack ...
STTRPhase I2002Department of Health and Human Services National Institutes of Health -
IMMUNOLIPOSOME MEDIATED GENE THERAPY FOR PROSTATE CANCER
Amount: $138,625.00N/A
STTRPhase I1999Department of Health and Human Services
